Loading...
01/10 19:55
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presented strong financial performance with a 40% revenue increase and EPS beat, despite a slight gross margin decline. Guidance was optimistic, with raised revenue expectations and positive free cash flow projected by 2025. The Q&A highlighted potential growth in Europe post-EU MDR approval and OPSB expansion. Despite some regulatory and economic challenges, the overall sentiment is positive, with strong growth and strategic plans in place. The lack of a share repurchase or dividend program slightly tempers the positive outlook, but the overall impact is expected to be positive in the short term.
EPS Reported EPS is $-0.29, compared to expectations of $-0.33.
Total Revenue $52.7 million, representing a 40% increase year-over-year.
US Revenue $42.9 million, a 52% increase year-over-year.
International Revenue $9.8 million, representing a 5% increase year-over-year.
Trauma and Deformity Revenue $36.4 million, a 35% increase year-over-year.
Scoliosis Revenue $15.6 million, a 62% increase year-over-year.
Gross Profit Margin 68%, down from 71% year-over-year, primarily due to a $3 million adjustment from reclassifying expenses.
Adjusted EBITDA $3.0 million, more than double the $1.3 million from the prior year.
Free Cash Flow Usage $3.7 million, a 70% reduction compared to the year-to-date average for the first three quarters of 2024.
Cash and Investments $70.8 million in cash, short-term investments, and restricted cash.
Operating Expenses $49.6 million, a 43% increase year-over-year, driven by restructuring charges and the addition of Boston OMP.
New Product Launches: Launched several new products including PMP tibia, cannulated screws, and Boston OMP sales, with expectations for continued growth from these products.
Innovative Product Development: Introduced new scoliosis brace sensor, patient compliance software, and additional DF2 sizes, expanding the use of OPSB products.
Market Expansion: Expanded clinic business in Indianapolis, Florida, and Colorado, with plans for four new territories in 2025.
International Market Growth: Anticipated EU MDR approval expected to drive growth in the EU Spine franchise.
Operational Efficiency: Consolidated production from Israel to the US to reduce supply risk and improve management of the ApiFix product line.
Financial Performance: Achieved $52.7 million in revenue for Q4 2024, a 40% increase year-over-year, with a focus on improving adjusted EBITDA and cash flow.
Strategic Shift: Shifted focus towards OPSB business, which is generating higher contribution margins than the implant business.
Long-term Goals: Aiming to help one million kids annually and achieve free cash flow positivity by Q4 2025.
Regulatory Issues: The company is awaiting EU MDR approval, which is an expensive process but necessary for expanding their product offerings in the EU market.
Supply Chain Challenges: The decision to slow sales shipments to South America, particularly Brazil, was made to reduce accounts receivable balances affected by rapid currency fluctuations.
Restructuring Charges: A $3.7 million restructuring charge was incurred due to the closure of the OP Israel office, moving production to the US to reduce supply risk.
Economic Factors: The rising dollar against South American currencies has negatively impacted receivables collection and international sales.
Competitive Pressures: The company acknowledges scrutiny from external macro dynamics and competitive pressures, although they believe their market position is strong.
Market Dynamics: Potential tariffs and government changes could impact operations, although the company expects minimal effects.
Market Dominance: OrthoPediatrics aims to achieve market dominance in the $500 million pediatric orthopedic implants market over the next several years.
Growth Strategy: The company plans to execute a strategy focused on expanding its OPSB business, which is generating higher contribution margins than its implant business.
Product Development: OrthoPediatrics is committed to delivering new products and technologies that meet major unmet needs in pediatric orthopedics.
International Expansion: The company is exploring further expansion opportunities for OPSB outside the US in 2025.
Surgeon Training: OrthoPediatrics hosted 132 unique training experiences for over 2,700 healthcare professionals, emphasizing its commitment to education in pediatric orthopedics.
2025 Revenue Guidance: OrthoPediatrics expects full-year 2025 revenue to be in the range of $235 to $242 million, representing year-over-year growth of 15% to 18%.
Adjusted EBITDA Guidance: The company anticipates adjusted EBITDA of $15 million to $17 million for 2025.
Free Cash Flow Guidance: OrthoPediatrics expects to achieve its first quarter of positive free cash flow in the fourth quarter of 2025.
Gross Margin Guidance: The company expects gross margins to remain in the range of 72% to 73% for the next several years.
Set Deployment Guidance: OrthoPediatrics expects approximately $15 million of new sets deployed in 2025.
Shareholder Return Plan: The company is focused on creating substantial shareholder value through aggressive execution of its strategy, aiming for free cash flow positivity by the fourth quarter of 2025. They expect to generate between $15 million to $17 million of adjusted EBITDA in 2025 and anticipate delivering their first quarter of positive free cash flow in the fourth quarter of 2025.
Share Repurchase Program: None
Dividend Program: None
The earnings call indicates strong financial performance with improved EBITDA and reduced free cash flow usage. The company is poised for growth with new product launches and international expansion, particularly in the pediatric space, benefiting from competitors exiting. Despite increased operating expenses, profitability improvements are sustainable, and revenue guidance has been raised. The Q&A section highlights management's confidence in growth and strategic initiatives, with some uncertainties in market share data and 7D placements. Overall, the positive outlook and strategic focus suggest a likely positive stock price movement.
The earnings call highlighted strong revenue growth, particularly in Scoliosis and adjusted EBITDA improvement. Despite a decline in gross profit margin, operational efficiencies and revenue growth led to a reduced net loss per share. The Q&A session revealed positive sentiment towards clinic expansion and international growth, although some guidance was vague. The company's rapid expansion and product launches, coupled with strong performance in Trauma, suggest a positive outlook. However, the lack of clear guidance and margin decline may temper the positive sentiment, resulting in an overall positive rating.
The earnings call presented strong financial performance with a 40% revenue increase and EPS beat, despite a slight gross margin decline. Guidance was optimistic, with raised revenue expectations and positive free cash flow projected by 2025. The Q&A highlighted potential growth in Europe post-EU MDR approval and OPSB expansion. Despite some regulatory and economic challenges, the overall sentiment is positive, with strong growth and strategic plans in place. The lack of a share repurchase or dividend program slightly tempers the positive outlook, but the overall impact is expected to be positive in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
